Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abidol
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abidol is an antiviral drug that has been investigated for the treatment of coronavirus disease 2019 (COVID-19). It has been studied in various clinical settings, including prospective/retrospective randomized controlled clinical studies and retrospective cohort studies, to evaluate its efficacy and safety in patients with COVID-19. While some studies suggest a potential role in reducing in-hospital mortality and shortening viral shedding duration, others indicate no superior efficacy compared to other antiviral drugs. Gastrointestinal side effects and an increase in bilirubin have been noted as potential adverse reactions.
- Brand names
- Arbidol
- Other names
- abidol hydrochloride
02
Targets
HMPV F (Human metapneumovirus fusion protein)HA stem (Influenza A hemagglutinin stem region)Mpro (3C-like proteinase of SARS-CoV-2)SARS-CoV-2 spike
Beyond the preview
Go deeper on abidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abidol.